What Bears Saw Before OptimizeRx Slid

If you backed the bullish thesis on OptimizeRx, the past year will not look anything like the optimistic analyst spreadsheets from late 2025. For OptimizeRx shareholders, the loss over the past year was 48.7%, including dividends. If you had committed capital on 4 November 2025, expecting DAAP-driven recurring revenue, rising margins and a future P/E in the mid-20s, what exactly did that original story fail to account for?

The useful thing about a Narrative is that the reasoning is checkable: the assumptions sit beside the argument, and together they imply an estimated Fair Value you can disagree with.

OptimizeRx has already moved. Pinpoint other ways to investigate the theme among 38 healthcare AI stocks.

The Two Competing Stories Around OptimizeRx Back Then

The shares cost US$18.78 at the start, and anyone looking at OptimizeRx had to pick between two sharply different stories that still sounded reasonable on the information available.

The bullish narrative put Fair Value at US$27, arguing that revenue could grow 12.3% a year with profit margins rising to 18.1%, supported by DAAP subscriptions and AI tools that were expected to shift the mix toward higher margin recurring contracts.

The bearish view set Fair Value at US$11, assuming 7.2% annual revenue growth and highlighting data privacy regulation as a key risk that could restrict OptimizeRx's data driven offerings and weigh on future demand.

What The Results Changed For The OptimizeRx Story

The clearest development for OptimizeRx was the launch of CopayCue and the planned integration of authenticated EHR and e prescribing inventory with PulsePoint. This supported the bullish idea of deeper EHR embedment and more workflow tools. At the same time, reported revenue dropped from US$29.195m in Q2 2025 to US$20.504m in Q2 2026 and net income swung from a profit to a loss, so the evidence cut both ways.

The practical lesson is that big product launches and new partnerships do not automatically solve the profitability puzzle. When you see a growth story built on higher margins, keep checking reported net margin and absolute profit against the original forecast, quarter by quarter.

What You Would Be Paying For In OptimizeRx Today

With OptimizeRx now trading at US$9.82, the selected Narrative puts Fair Value above that level and links the gap to expectations around AI driven software, authenticated EHR inventory and margin discipline, rather than a quick rebound in headline revenue.

To see the past year’s 48.7% fall as a potential opening rather than a red flag, a buyer would need to believe DAAP, DSP integrations and mid tier pharma clients can reliably turn into higher margin recurring software income.

"The main factor that has to go right is the company successfully converting DSP integrations, AI-enabled DAAP growth, and expanding mid-tier and medtech relationships into durable, higher-margin software and subscription revenue, while managing customer concentration risks."

The price and this Narrative do not agree. → Uncover what this Narrative says OptimizeRx is actually worth

Which Company Could Surprise You Next?

Passing on this one could have spared you a loss. Where might you find the opposite surprise? Start looking for companies whose prices leave room for a better outcome than investors expect. These three trade below our estimated value.

• Company 1 - 50% below our estimate - experiments with exporting a dominant marketplace and payments ecosystem into a new country.
• Company 2 - 49% below our estimate - extends a subscription identity platform from airport lanes into government and enterprise access.
• Company 3 - 25% below our estimate - embeds AI assistants and cloud tools deeper into everyday productivity and software development workflows.

Those are three of them. See every one of the 35 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com